1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move

Novartis is taking a more calculated and strategic approach to its growth. There are $200 billion reasons healthcare companies want to produce GLP-1 weight loss drugs. At that size, the market potential is huge, and the opportunities for revenue growth are plentiful. But it also means that competition will be fierce. And with some highly effective treatments already approved and available, the bar is set high for any new drug that wants to take a slice of that lucrative market. Not every company is jumping ...